Draft Guidance for Industry on Listing of Ingredients in Tobacco Products; Availability, 56842-56843 [E9-26466]
Download as PDF
56842
Federal Register / Vol. 74, No. 211 / Tuesday, November 3, 2009 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number
of
respondents
Respondents
Phase I ..................................
Form name
Section Foreman ..................
Phase I Section Foreman
Form.
Phase I Baseline Form .........
Phase I 1 month form ...........
Phase I Focus Group Questions.
Phase II Section Foreman
Form.
Phase II Baseline Form ........
Phase II 1, 3, and 6 months
forms.
Mine Workers .......................
Mine Workers .......................
Mine Workers .......................
Phase II .................................
Section Foreman ..................
Mine Workers .......................
Mine Workers .......................
Dated: October 28, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–26395 Filed 11–2–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0524]
Draft Guidance for Industry on Listing
of Ingredients in Tobacco Products;
Availability
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSKH9S0YB1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Listing of Ingredients
in Tobacco Products.’’ The draft
guidance document is intended to assist
persons making tobacco product
ingredient submissions to FDA as
required by section 904 of the Federal
Food, Drug, and Cosmetic Act (the act)
as added by the Family Smoking
Prevention and Tobacco Control Act
(Tobacco Control Act).
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
written or electronic comments on the
draft guidance by November 13, 2009.
ADDRESSES: Submit written requests for
single copies of the draft guidance
document entitled ‘‘Listing of
Ingredients in Tobacco Products’’ to the
Center for Tobacco Products, Food and
Drug Administration, 9200 Corporate
Blvd., Rockville, MD 20850–3229. Send
VerDate Nov<24>2008
18:15 Nov 02, 2009
Jkt 220001
one self-addressed adhesive label to
assist that office in processing your
request or include a fax number to
which the draft guidance document may
be sent.
Submit electronic comments to https://
www.regulations.gov. Submit written
comments on the guidance to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Michele Mital, Center for Tobacco
Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850–3229, 301–796–
4800, Michele.Mital@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
On June 22, 2009, the President
signed the Tobacco Control act (Public
Law 111–31) into law. The Tobacco
Control Act amended the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 301 et seq.) by, among other
things, adding a new chapter granting
FDA important new authority to
regulate the manufacture, marketing,
and distribution of tobacco products to
protect the public health generally and
to reduce tobacco use by minors.
Section 904(a)(1) of the act, as
amended by the Tobacco Control Act,
requires each tobacco product
manufacturer or importer, or agent
thereof, to submit ‘‘a listing of all
ingredients, including tobacco,
substances, compounds, and additives
that are * * * added by the
manufacturer to the tobacco, paper,
filter, or other part of each tobacco
product by brand and by quantity in
each brand and subbrand.’’ Since the
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Average
burden per
response
(in hours)
1
1
10/60
9
9
9
1
1
1
20/60
30/60
1
6
12
10/60
54
54
1
6
20/60
25/60
Tobacco Control act was enacted on
June 22, 2009, the information required
under section 904(a)(1) must be
submitted to FDA by December 22,
2009, and include the ingredients added
as of the date of submission. While
electronic submission of ingredient
listing information is not required, FDA
is strongly encouraging electronic
submission to facilitate efficiency and
timeliness of data management and
collection. To that end, FDA designed
the eSubmitter application to streamline
the data entry process for ingredient
listing. This tool allows for importation
of large quantities of structured data,
attachments of files (e.g., in portable
document format (PDFs) and certain
media files), and automatic
acknowledgement of FDA’s receipt of
submissions.
II. Significance of Guidance
FDA is issuing this draft guidance
document consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance, when
finalized, will represent the agency’s
current thinking on ‘‘Listing of
Ingredients in Tobacco Products.’’ It
does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statute
and regulations.
III. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. The guidance
E:\FR\FM\03NON1.SGM
03NON1
Federal Register / Vol. 74, No. 211 / Tuesday, November 3, 2009 / Notices
document and received comments may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
IV. Paperwork Reduction Act of 1995
This draft guidance contains proposed
collections of information that are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501–3520). As
required by the PRA, FDA has
published an analysis of the information
collection concerning the submission of
ingredient information (74 FR 45219,
September 1, 2009, as corrected by 74
FR 47257, September 15, 2009) and will
submit it for OMB approval.
Intravascular Device-Related Infections
published in 2002. These guidelines
provide evidence-based
recommendations for preventing
intravascular catheter-related infections.
DATES: Comments must be received on
or before December 3, 2009.
ADDRESSES: Comments on the Draft
Guideline for the Prevention of
Intravascular Catheter-Related
Infections should be submitted by email to BSI@cdc.gov or by mail to CDC,
Division of Healthcare Quality
Promotion, Attn: Resource Center, 1600
Clifton Rd., NE., Mailstop A–31,
Atlanta, Georgia 30333; or by fax 404–
639–4049.
V. Electronic Access
An electronic version of the guidance
document is available on the Internet at
https://www.regulations.gov and https://
www.fda.gov/TobaccoProducts/
GuidanceComplianceRegulatory
Information/default.htm
Dated: October 27, 2009.
Tanja Popovic,
Chief Science Officer, Centers for Disease
Control and Prevention.
[FR Doc. E9–26393 Filed 11–2–09; 8:45 am]
BILLING CODE 4163–18–P
Dated: October 29, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–26466 Filed 10–30–09; 11:15
am]
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Draft Guideline for the Prevention of
Intravascular Catheter-Related
Infections
mstockstill on DSKH9S0YB1PROD with NOTICES
AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (DHHS).
ACTION: Notice of availability and
request for public comment.
SUMMARY: This notice is a request for
review of and comment on the Draft
Guideline for the Prevention of
Intravascular Catheter-Related
Infections, available on the following
Web site: https://www.cdc.gov/
publiccomments/.
This document is for use by infection
prevention staff, healthcare
epidemiologists, healthcare
administrators, nurses, other healthcare
providers, and persons responsible for
developing, implementing, and
evaluating infection prevention and
control programs for healthcare settings
across the continuum of care. The
guideline updates and expands the
Guideline for the Prevention of
VerDate Nov<24>2008
18:15 Nov 02, 2009
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Career Development &
Fellowship Applications.
Date: November 4, 2009.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call)
Contact Person: Raul A Saavedra, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS, Nsc; 6001
Executive Blvd., Ste. 3208, Bethesda, MD
20892–9529, 301–496–9223,
saavedrr@ninds.nih.gov.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
56843
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; K01 Conflict Review.
Date: November 19, 2009.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call)
Contact Person: Joann Mcconnell, PhD,
Scientific Review Administrator, Scientific
Review Branch, NIH/NINDS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–5324, mcconnej@ninds.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; K99 Special Review.
Date: November 20, 2009.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call)
Contact Person: Joann Mcconnell, PhD,
Scientific Review Administrator, Scientific
Review Branch, NIH/NINDS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529, (301)
496–5324, mcconnej@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: October 21, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–25923 Filed 11–2–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0523]
Product Tracing Systems for Food;
Public Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; request for comment.
SUMMARY: The Food and Drug
Administration (FDA), in collaboration
with the United States Department of
Agriculture, Food Safety and Inspection
Service (FSIS), is announcing a public
meeting regarding product tracing
systems for food intended for humans
E:\FR\FM\03NON1.SGM
03NON1
Agencies
[Federal Register Volume 74, Number 211 (Tuesday, November 3, 2009)]
[Notices]
[Pages 56842-56843]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-26466]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-D-0524]
Draft Guidance for Industry on Listing of Ingredients in Tobacco
Products; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Listing of
Ingredients in Tobacco Products.'' The draft guidance document is
intended to assist persons making tobacco product ingredient
submissions to FDA as required by section 904 of the Federal Food,
Drug, and Cosmetic Act (the act) as added by the Family Smoking
Prevention and Tobacco Control Act (Tobacco Control Act).
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit written or electronic comments on the draft guidance
by November 13, 2009.
ADDRESSES: Submit written requests for single copies of the draft
guidance document entitled ``Listing of Ingredients in Tobacco
Products'' to the Center for Tobacco Products, Food and Drug
Administration, 9200 Corporate Blvd., Rockville, MD 20850-3229. Send
one self-addressed adhesive label to assist that office in processing
your request or include a fax number to which the draft guidance
document may be sent.
Submit electronic comments to https://www.regulations.gov. Submit
written comments on the guidance to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Identify comments with the docket number found in
brackets in the heading of this document. See the SUPPLEMENTARY
INFORMATION section for electronic access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Michele Mital, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850-3229, 301-796-4800, Michele.Mital@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
On June 22, 2009, the President signed the Tobacco Control act
(Public Law 111-31) into law. The Tobacco Control Act amended the
Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 301 et seq.)
by, among other things, adding a new chapter granting FDA important new
authority to regulate the manufacture, marketing, and distribution of
tobacco products to protect the public health generally and to reduce
tobacco use by minors.
Section 904(a)(1) of the act, as amended by the Tobacco Control
Act, requires each tobacco product manufacturer or importer, or agent
thereof, to submit ``a listing of all ingredients, including tobacco,
substances, compounds, and additives that are * * * added by the
manufacturer to the tobacco, paper, filter, or other part of each
tobacco product by brand and by quantity in each brand and subbrand.''
Since the Tobacco Control act was enacted on June 22, 2009, the
information required under section 904(a)(1) must be submitted to FDA
by December 22, 2009, and include the ingredients added as of the date
of submission. While electronic submission of ingredient listing
information is not required, FDA is strongly encouraging electronic
submission to facilitate efficiency and timeliness of data management
and collection. To that end, FDA designed the eSubmitter application to
streamline the data entry process for ingredient listing. This tool
allows for importation of large quantities of structured data,
attachments of files (e.g., in portable document format (PDFs) and
certain media files), and automatic acknowledgement of FDA's receipt of
submissions.
II. Significance of Guidance
FDA is issuing this draft guidance document consistent with FDA's
good guidance practices regulation (21 CFR 10.115). The draft guidance,
when finalized, will represent the agency's current thinking on
``Listing of Ingredients in Tobacco Products.'' It does not create or
confer any rights for or on any person and does not operate to bind FDA
or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statute and regulations.
III. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. The guidance
[[Page 56843]]
document and received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
IV. Paperwork Reduction Act of 1995
This draft guidance contains proposed collections of information
that are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520).
As required by the PRA, FDA has published an analysis of the
information collection concerning the submission of ingredient
information (74 FR 45219, September 1, 2009, as corrected by 74 FR
47257, September 15, 2009) and will submit it for OMB approval.
V. Electronic Access
An electronic version of the guidance document is available on the
Internet at https://www.regulations.gov and https://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/default.htm
Dated: October 29, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-26466 Filed 10-30-09; 11:15 am]
BILLING CODE 4160-01-S